AR093309A1 - Neurotoxinas recombinantes de clostridium botulinum - Google Patents
Neurotoxinas recombinantes de clostridium botulinumInfo
- Publication number
- AR093309A1 AR093309A1 ARP130103981A ARP130103981A AR093309A1 AR 093309 A1 AR093309 A1 AR 093309A1 AR P130103981 A ARP130103981 A AR P130103981A AR P130103981 A ARP130103981 A AR P130103981A AR 093309 A1 AR093309 A1 AR 093309A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- clostridium botulinum
- contiguous nucleotide
- nucleotide sequence
- bont
- Prior art date
Links
- 239000002581 neurotoxin Substances 0.000 title abstract 2
- 231100000618 neurotoxin Toxicity 0.000 title abstract 2
- 241000193155 Clostridium botulinum Species 0.000 title 1
- 108030001720 Bontoxilysin Proteins 0.000 abstract 3
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 abstract 3
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201219602A GB201219602D0 (en) | 2012-10-31 | 2012-10-31 | Recombinant clostridium botulinum neurotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093309A1 true AR093309A1 (es) | 2015-05-27 |
Family
ID=47358958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103981A AR093309A1 (es) | 2012-10-31 | 2013-10-31 | Neurotoxinas recombinantes de clostridium botulinum |
| ARP190103867A AR117738A2 (es) | 2012-10-31 | 2019-12-26 | Neurotoxinas recombinantes de clostridium botulinum |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103867A AR117738A2 (es) | 2012-10-31 | 2019-12-26 | Neurotoxinas recombinantes de clostridium botulinum |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10030238B2 (Direct) |
| EP (3) | EP2914282B1 (Direct) |
| JP (2) | JP2019068823A (Direct) |
| KR (2) | KR102188539B1 (Direct) |
| CN (2) | CN104755098A (Direct) |
| AR (2) | AR093309A1 (Direct) |
| AU (3) | AU2013340610B2 (Direct) |
| BR (1) | BR112015005384A2 (Direct) |
| CA (1) | CA2885519A1 (Direct) |
| DK (2) | DK2914282T3 (Direct) |
| EA (1) | EA201590794A8 (Direct) |
| ES (2) | ES2662402T3 (Direct) |
| GB (1) | GB201219602D0 (Direct) |
| HU (2) | HUE048802T2 (Direct) |
| IL (1) | IL237623B (Direct) |
| IN (1) | IN2015MN00436A (Direct) |
| MX (2) | MX367080B (Direct) |
| NO (1) | NO2914282T3 (Direct) |
| NZ (1) | NZ705575A (Direct) |
| PL (2) | PL2914282T3 (Direct) |
| PT (2) | PT2914282T (Direct) |
| SG (2) | SG10201701140WA (Direct) |
| TW (3) | TWI626307B (Direct) |
| UA (1) | UA118837C2 (Direct) |
| WO (1) | WO2014068317A1 (Direct) |
| ZA (1) | ZA201501449B (Direct) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| CN115925835A (zh) * | 2015-03-26 | 2023-04-07 | 哈佛大学校长及研究员协会 | 工程改造的肉毒杆菌神经毒素 |
| WO2017063743A1 (en) | 2015-10-14 | 2017-04-20 | Merz Pharma Gmbh & Co. Kgaa | Improvements to ultrasound-based therapy of photoaged tissue |
| EP3423084B1 (en) | 2016-03-02 | 2021-09-01 | Merz Pharma GmbH & Co. KGaA | Composition comprising botulinum toxin |
| EP3263710A1 (en) * | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| JP7100020B2 (ja) | 2016-08-24 | 2022-07-12 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたボツリヌス神経毒素 |
| EP3639848A3 (en) | 2016-09-13 | 2020-12-16 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
| WO2018233813A1 (en) | 2017-06-20 | 2018-12-27 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
| US11155802B2 (en) | 2017-07-06 | 2021-10-26 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum neurotoxins with increased duration of effect |
| AU2018347514C1 (en) | 2017-10-11 | 2025-01-02 | Illustris Pharmaceuticals, Inc. | Methods and compositions for topical delivery |
| TWI822723B (zh) * | 2018-01-29 | 2023-11-21 | 英商艾普森生物製藥有限公司 | 非神經元性 SNARE 裂解的肉毒桿菌神經毒素、裂解 hSNAP-23 之活體外方法、及經修飾 BoNT/A L 鏈蛋白酶之用途 |
| EP3752128B1 (de) * | 2018-02-16 | 2025-01-15 | preclinics discovery GmbH | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
| GB201815844D0 (en) | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| GB202015618D0 (en) | 2020-10-01 | 2020-11-18 | Ipsen Biopharm Ltd | Method for producing beta-trypsin |
| CN115819526A (zh) * | 2022-12-02 | 2023-03-21 | 海雅美生物技术(珠海)有限公司 | 一种重组肉毒杆菌神经毒素及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| NZ308772A (en) * | 1995-05-17 | 1999-04-29 | Du Pont | Recombinant baculovirus insecticides |
| EP1119626B1 (en) | 1998-07-10 | 2008-01-02 | U.S. Army Medical Research Institute of Infectious Diseases | Botulinum neurotoxin vaccine |
| ATE348178T1 (de) * | 1999-08-25 | 2007-01-15 | Allergan Inc | Aktivierbare rekombinante neurotoxine |
| US7374896B2 (en) | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US20110111483A1 (en) | 2004-06-30 | 2011-05-12 | Allergan, Inc. | Optimizing Expression of Active Botulinum Toxin Type E |
| WO2006011966A1 (en) * | 2004-06-30 | 2006-02-02 | Allergan, Inc. | Optimizing expression of active botulinum toxin type e |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005002978B4 (de) * | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| BRPI0508299A (pt) * | 2005-03-03 | 2007-07-31 | Allergan Inc | sistema livre de produto animal e processo para purificação de uma toxina botulina |
| DK1926744T4 (en) * | 2005-09-19 | 2019-01-28 | Allergan Inc | CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES |
| US20070218084A1 (en) * | 2005-12-30 | 2007-09-20 | Fondazione Pierfranco E Luisa Mariani- Onlus | Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy |
| JP2009543558A (ja) * | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
| US8486422B2 (en) | 2007-07-26 | 2013-07-16 | Allergan, Inc. | Methods of activating clostridial toxins |
| RU2535003C2 (ru) | 2008-12-10 | 2014-12-10 | Аллерган, Инк. | Фармацевтические композиции токсина клостридий |
| GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| EP2419128B1 (en) * | 2009-04-14 | 2018-06-06 | Medical College of Wisconsin, Inc. | Engineered botulinum neurotoxin |
| JP2013514091A (ja) * | 2009-12-16 | 2013-04-25 | アラーガン、インコーポレイテッド | 組込型プロテアーゼ切断部位結合ドメインを含む改変クロストリジウム毒素 |
| WO2012112434A1 (en) | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Inhibiting aberrant blood vessel formation using retargeted endopeptidases |
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| JP7100020B2 (ja) * | 2016-08-24 | 2022-07-12 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたボツリヌス神経毒素 |
-
2012
- 2012-10-31 GB GB201219602A patent/GB201219602D0/en not_active Ceased
-
2013
- 2013-10-31 KR KR1020157010099A patent/KR102188539B1/ko active Active
- 2013-10-31 TW TW102139558A patent/TWI626307B/zh not_active IP Right Cessation
- 2013-10-31 KR KR1020207026658A patent/KR102264478B1/ko active Active
- 2013-10-31 PL PL13811605T patent/PL2914282T3/pl unknown
- 2013-10-31 ES ES13811605.8T patent/ES2662402T3/es active Active
- 2013-10-31 HU HUE17201198A patent/HUE048802T2/hu unknown
- 2013-10-31 NO NO13811605A patent/NO2914282T3/no unknown
- 2013-10-31 TW TW108125708A patent/TW202012622A/zh unknown
- 2013-10-31 EP EP13811605.8A patent/EP2914282B1/en active Active
- 2013-10-31 US US14/427,234 patent/US10030238B2/en active Active
- 2013-10-31 CN CN201380047542.8A patent/CN104755098A/zh active Pending
- 2013-10-31 DK DK13811605.8T patent/DK2914282T3/en active
- 2013-10-31 PT PT138116058T patent/PT2914282T/pt unknown
- 2013-10-31 UA UAA201502159A patent/UA118837C2/uk unknown
- 2013-10-31 MX MX2015005156A patent/MX367080B/es active IP Right Grant
- 2013-10-31 NZ NZ705575A patent/NZ705575A/en not_active IP Right Cessation
- 2013-10-31 SG SG10201701140WA patent/SG10201701140WA/en unknown
- 2013-10-31 IN IN436MUN2015 patent/IN2015MN00436A/en unknown
- 2013-10-31 WO PCT/GB2013/052845 patent/WO2014068317A1/en not_active Ceased
- 2013-10-31 EP EP20153122.5A patent/EP3673914B1/en active Active
- 2013-10-31 BR BR112015005384A patent/BR112015005384A2/pt not_active Application Discontinuation
- 2013-10-31 PL PL17201198T patent/PL3326644T3/pl unknown
- 2013-10-31 DK DK17201198.3T patent/DK3326644T3/da active
- 2013-10-31 HU HUE13811605A patent/HUE036764T2/hu unknown
- 2013-10-31 PT PT172011983T patent/PT3326644T/pt unknown
- 2013-10-31 CA CA2885519A patent/CA2885519A1/en not_active Abandoned
- 2013-10-31 SG SG11201502372SA patent/SG11201502372SA/en unknown
- 2013-10-31 AR ARP130103981A patent/AR093309A1/es active IP Right Grant
- 2013-10-31 ES ES17201198T patent/ES2788199T3/es active Active
- 2013-10-31 EP EP17201198.3A patent/EP3326644B1/en active Active
- 2013-10-31 TW TW107110108A patent/TWI673361B/zh not_active IP Right Cessation
- 2013-10-31 EA EA201590794A patent/EA201590794A8/ru unknown
- 2013-10-31 CN CN201910795176.3A patent/CN110499321A/zh active Pending
- 2013-10-31 AU AU2013340610A patent/AU2013340610B2/en not_active Ceased
-
2015
- 2015-03-03 ZA ZA2015/01449A patent/ZA201501449B/en unknown
- 2015-03-08 IL IL237623A patent/IL237623B/en active IP Right Grant
- 2015-04-23 MX MX2019009222A patent/MX2019009222A/es unknown
-
2018
- 2018-05-21 AU AU2018203556A patent/AU2018203556B2/en not_active Ceased
- 2018-12-10 JP JP2018230980A patent/JP2019068823A/ja not_active Ceased
-
2019
- 2019-12-26 AR ARP190103867A patent/AR117738A2/es unknown
-
2020
- 2020-02-05 JP JP2020017612A patent/JP2020078321A/ja active Pending
- 2020-09-30 AU AU2020244481A patent/AU2020244481A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093309A1 (es) | Neurotoxinas recombinantes de clostridium botulinum | |
| AR092712A1 (es) | Una proteina con actividad cetosa 3-epimerasa | |
| AR118019A2 (es) | Métodos para la elaboración de polipéptidos procesados proteolíticamente | |
| MX387336B (es) | Enzimas de clostridium histolyticum y metodos para el uso de los mismos. | |
| MX2023001119A (es) | Variantes de enzimas y polinucleotidos que las codifican. | |
| MX2019009191A (es) | Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas. | |
| MX375778B (es) | Variantes mejoradas de enzimas. | |
| MX2023001319A (es) | Polipeptidos condicionalmente activos. | |
| BR112012004823A8 (pt) | Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| UY34227A (es) | Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo | |
| WO2014145820A3 (en) | Multiple tagging of long dna fragments | |
| MX372950B (es) | Anticuerpos. | |
| AR083354A1 (es) | Polipeptidos variantes cbh i (celobiohidrolasas i) con reducida inhibicion de producto | |
| BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
| AR087885A1 (es) | Enzimas utiles para la industria alimenticia | |
| MX2022007107A (es) | Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas. | |
| MX2021005980A (es) | Adenovirus y metodos para usar adenovirus. | |
| MX2016006277A (es) | Secuencia de endolisina kz144 modificada. | |
| AR102410A1 (es) | Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa | |
| EA201691011A1 (ru) | Последовательность модифицированного эндолизина el188 | |
| BR112017003228A2 (pt) | genes chromobacterium subtsugae | |
| MX2016003405A (es) | Hetero-transglicosilasa novedosa y usos de la misma. | |
| AR102762A1 (es) | Secuencia de oligonucleótidos para uso en ingeniería de rutas metabólicas | |
| BR112018001855A2 (pt) | expressão de enzimas beta-xilosidase recombinantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |